NARAYANA HRUDAYALAYA share price has zoomed 7% and is presently trading at Rs 1,260.0.
Meanwhile, the BSE HEALTHCARE index is at 42,007.8 (up 0.9%).
Among the top gainers in the BSE HEALTHCARE index today are GSK Pharma (up 6.3%) and SUVEN PHARMACEUTICALS (up 4.7%).
DR. LAL PATHLABS (down 1.3%) and CAPLIN POINT (down 1.2%) are among the top losers today.
Over the last one year, NARAYANA HRUDAYALAYA has moved up from Rs 996.0 to Rs 1,260.0, registering a gain of Rs 264.0 (up 26.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,021.8 to 42,007.8, registering a gain of 49.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 132.2%), GSK Pharma (up 119.5%) and Glenmark Pharma (up 115.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 80,905.3 (up 0.1%).
The top gainers among the BSE Sensex today are Titan (up 2.5%) and Asian Paints (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.
In the meantime, NSE Nifty is at 24,781.9 (up 0.3%). Divis Laboratories and Titan are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,216.1 to 80,905.3, registering a gain of 15,689.2 points (up 24.1%).
NARAYANA HRUDAYALAYA net profit grew 9.5% YoY to Rs 2,015 million for the quarter ended June 2024, compared to a profit of Rs 1,840 million a year ago. Net sales rose 8.7% to Rs 13,410 million during the period as against Rs 12,334 million in April-June 2023.
For the year ended March 2024, NARAYANA HRUDAYALAYA reported 30.2% increase in net profit to Rs 7,896 million compared to net profit of Rs 6,066 million during FY23. Revenue of the company grew 10.9% to Rs 50,182 million during FY24.
The current Price to earnings ratio of NARAYANA HRUDAYALAYA, based on rolling 12 month earnings, stands at 31.9.
Equitymaster requests your view! Post a comment on "NARAYANA HRUDAYALAYA Gains 7%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!